Last updated 15 days ago
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
1633 patients around the world
Available in Puerto Rico, Mexico, United States
Eli Lilly and Company
6Research sites
1633Patients around the world
This study is for people with
Migraine
Requirements for the patient
To 17 Years
All Gender
Medical requirements
- Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria.History of migraine attacks for more than 6 months.Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit.Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours.Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator.Participant must be able to swallow a tablet.For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening.Participants must weigh at least 15 kilograms (kg).
- Participants must not be pregnant or nursing.Participants must not have any acute, serious, or unstable medical condition.Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator.
Sites
Centro de Investigación Médica Aguascalientes - CIMA
Recruiting
Unidad de Investigación en Salud
Recruiting
Hospital Infantil de México Federico Gómez
Recruiting
Hospital Civil de Guadalajara Fray Antonio Alcalde
Recruiting
Panamerican Clinical Research S.A. de C.V
Recruiting
Hospital Universitario Dr. José Eleuterio González
Recruiting
StudyPIONEER-PEDS1
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Requirements
To 17 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04396236
